Spectrophotometric Determination of Etravirine in Bulk and Pharmaceutical Formulations
- 1 Department of Chemistry, Acharya Nagarjuna University, Guntur, India
- 2 Department of Chemistry, Acharya Nagarjuna University, Guntur, India
- 3 Department of Chemistry, Acharya Nagarjuna University, Guntur, India
Abstract
Two simple, rapid, sensitive, accurate, precise and economical Visible Spectrophotometric methods have been developed for the determination of Etravirine in pure and pharmaceutical formulations. These methods (A and B) were based on nucleophilic substitution and oxidative coupling reactions of Etravirine by 1,2 - naphtha quinone-4-sulphonate (NQS) in alkaline medium and 3-methyl-2-benzothiazolinone hydrazone (MBTH) in acidic medium with the maximum absorbance at 414 nm and 635 nm respectively. Linearity was obtained in the concentration range of 5 - 30 μg/ml and 2 - 10 μg/ml which was corroborated by the correlation coefficient (r) values of 0.9995 and 0.9996 respectively. The methods developed were validated with respect to linearity, accuracy (recovery), precision, Sandell’s sensitivity, molar extinction coefficient and specificity. The proposed methods are successfully applied for the determination of Etravirine in bulk and pharmaceutical formulations and results were validated statistically by recovery studies.
- A. I. Maiga, D. Descamps, L. Morand-Joubert, I. Malet, A. Derache, M. Cisse, V. Koita, A. Akonde, B. Diarra, M. Wirden, A. Tounkara, Y. Verlinden, C. Katlama, D. Costagliola, B. Masquelier, V. Calvez and A.-G. Marcelin, “Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naive Patients Infected with Non-B HIV-1 Subtypes,” Antimicrobial Agents and Chemotherapy, Vol. 54, No. 2, 2010, pp. 728-733. http://dx.doi.org/10.1128/AAC.01335-09
- J. D. Croxtall, “Etravirine: A Review of Its Use in the Management of Treatment-Experienced Patients with HIV-1 Infection,” Drugs, Vol. 72, No. 6, 2012, pp. 847-869. http://dx.doi.org/10.2165/11209110-000000000-00000
- J. M. Tiraboschi, J. Niubo, A. Vila, S. Perez-Pujol and D. Podzamczer, “Etravirine Concentrations in CSF in HIV-Infected Patients,” Journal of Antimicrobial Chemotherapy, Vol. 67, No. 6, 2012, pp. 1446-1448. http://dx.doi.org/10.1093/jac/dks048
- A. Gutiérrez-Valencia, R. Martin-Pena, A. Torres-Cornejo, R. Ruiz-Valderas, J. R. Castillo-Ferrando and L. F. López-Cortés, “Intracellular and Plasma Pharmacokinetics of 400 mg of Etravirine Once Daily versus 200 mg of Etravirine Twice Daily in HIV-Infected Patients,” Journal of Antimicrobial Chemotherapy, Vol. 67, No. 3, 2012, pp. 681-684. http://dx.doi.org/10.1093/jac/dkr534
- C. V. Abobo, L. Wu, J. John, M. K. Joseph, T. R. Bates and D. Liang, “ LC-MS/MS Determination of Etravirine in Rat Plasma and Its Application in Pharmacokinetic Studies,” Journal of Chromatography B, Analaytical Technologies in the Biomed Life Sciences, Vol. 878, No. 36, 2010, pp. 3181-3186. http://dx.doi.org/10.1016/j.jchromb.2010.09.016
- S. Quaranta, C. Woloch, A. Paccou, M. Giocanti, C. Solas and B. Lacarellere, “Validation of an Electrospray Ionization LC-MS/MS Method for Quantitative Analysis of Raltegravir, Etravirine, and 9 Other Antiretroviral Agents in Human Plasma Samples,” Therapeutic Drug Monitoring, Vol. 31, No. 6, 2009, pp. 695-702.
- N. L. Rezk, N. R. White, S. H. Jennings and A. D. M. Kashuba, “A Novel LC-ESI-MS Method for the Simultaneous Determination of Etravirine, Daunavir and Ritonavir in Human Blood Plasma,” Talanta, Vol. 79, No. 5, 2009, pp. 1372-1378. http://dx.doi.org/10.1016/j.talanta.2009.06.005
- A. Fayet, A. Benguin, B. Zanolari, S. Lruchon, N. Guiguard, A. Telenti, M. Cavassani, H. F. Gunthard, T. Buclin, J. Biollaz, B. Rochat and L. A. Decosterd, “A LCTandem MS Assay for the Simultaneous Measurement of New Anti Retroviral Agents: Raltegravir, Maraviroc, Darunavir, and Etravirine,” Journal of Chromatography B, Vol. 877, No. 11-12, 2009, pp. 1057-1069. http://dx.doi.org/10.1016/j.jchromb.2009.02.057